CervoMed Q1 EPS Increased by Brookline Capital Management

CervoMed Inc. (NASDAQ:CRVO) – Equities researchers at Brookline Capital Management boosted their Q1 2025 EPS estimates for shares of CervoMed in a note issued to investors on Tuesday, March 18th. Brookline Capital Management analyst T. Bussian now expects that the company will post earnings of ($0.47) per share for the quarter, up from their previous forecast of ($0.48). Brookline Capital Management has a “Strong-Buy” rating on the stock. The consensus estimate for CervoMed’s current full-year earnings is ($1.88) per share. Brookline Capital Management also issued estimates for CervoMed’s Q2 2025 earnings at ($0.47) EPS, Q3 2025 earnings at ($0.37) EPS, Q4 2025 earnings at ($0.44) EPS and FY2025 earnings at ($1.75) EPS.

Other research analysts have also issued reports about the stock. HC Wainwright lowered shares of CervoMed from a “buy” rating to a “neutral” rating in a research note on Tuesday, December 17th. Roth Capital raised shares of CervoMed to a “strong-buy” rating in a research note on Thursday, December 5th. Roth Mkm upped their price target on shares of CervoMed from $15.00 to $20.00 and gave the stock a “buy” rating in a research note on Tuesday. Jones Trading raised shares of CervoMed from a “hold” rating to a “buy” rating and set a $15.00 price target for the company in a research note on Thursday, March 13th. Finally, Canaccord Genuity Group boosted their target price on shares of CervoMed from $12.00 to $21.00 and gave the stock a “buy” rating in a report on Tuesday. One research analyst has rated the stock with a sell rating, one has given a hold rating, five have issued a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat.com, the company currently has an average rating of “Moderate Buy” and an average price target of $27.50.

CervoMed Price Performance

CRVO opened at $9.37 on Thursday. CervoMed has a 1-year low of $1.80 and a 1-year high of $26.38. The company has a 50-day moving average of $2.87 and a 200-day moving average of $7.88.

CervoMed (NASDAQ:CRVO) last released its quarterly earnings results on Monday, March 17th. The company reported ($0.80) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.67) by ($0.13). CervoMed had a negative return on equity of 44.11% and a negative net margin of 118.68%. The firm had revenue of $2.16 million for the quarter, compared to analysts’ expectations of $1.51 million.

Institutional Investors Weigh In On CervoMed

A number of large investors have recently made changes to their positions in CRVO. Citizens Financial Group Inc. RI raised its holdings in shares of CervoMed by 13.2% during the third quarter. Citizens Financial Group Inc. RI now owns 30,509 shares of the company’s stock valued at $445,000 after acquiring an additional 3,553 shares during the period. FMR LLC purchased a new position in CervoMed during the third quarter valued at approximately $56,000. State Street Corp grew its position in CervoMed by 28.1% during the third quarter. State Street Corp now owns 104,456 shares of the company’s stock valued at $1,525,000 after purchasing an additional 22,903 shares in the last quarter. Barclays PLC grew its position in CervoMed by 323.6% during the third quarter. Barclays PLC now owns 7,748 shares of the company’s stock valued at $113,000 after purchasing an additional 5,919 shares in the last quarter. Finally, Geode Capital Management LLC grew its position in CervoMed by 13.9% during the third quarter. Geode Capital Management LLC now owns 114,934 shares of the company’s stock valued at $1,678,000 after purchasing an additional 14,042 shares in the last quarter. Institutional investors and hedge funds own 25.15% of the company’s stock.

CervoMed Company Profile

CervoMed Inc, a biotechnology company, engages in the development and commercialization of treatments for age-related neurologic disorders. Its lead drug candidate is neflamapimod, an orally administered small molecule brain penetrant for the treatment of dementia with Lewy bodies (DLB), Alzheimer's diseases, frontotemporal dementia, and ischemic stroke recovery.